Flu Vaccine Produces Robust Immune Responses
New vaccine of Vical Incorporated against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. Vical [...]
Flu Vaccine Solution in Spain: VLP Technology
Novavax, Inc. announced initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of Spain. ROVI will use the VLP technology to create a comprehensive influenza vaccine solution for the Spanish government under a new 60 million euro program sponsored and led by the Spanish Ministry of Health and [...]
DNA Vaccines against Swine Influenza A (H1N1) in Evaluation
Inovio Biomedical Corporation in collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania is evaluating DNA vaccine candidates against swine influenza A (H1N1) virus. These vaccines, delivered using Inovio’s proprietary electroporation technology, have the potential to provide protection against a broad scope of existing as well [...]
Protein Sciences Corporation Announced Production of H1N1 Swine Flu Vaccine
Protein Sciences Corporation (PSC) announced that it commenced manufacturing of a vaccine to protect humans against the H1N1 “swine flu” virus. The Company estimates that it can produce 100,000 doses this week and at least 100,000 doses per week thereafter. The vaccine, called PanBlok®, is made using PSC’s proprietary baculovirus and insect cell manufacturing technology. [...]
China’s First Influenza A (H1N1) Vaccine Order Goes to Sinovac
On June 14, 2009, Sinovac completed construction of the H1N1 virus seed bank necessary to produce a virus antigen and commenced production of the first batch of H1N1 vaccine. Sinovac expects to complete production of the first batch by the end of July.
Few days later Sinovac Biotech Ltd. announced the first order in [...]
DNA Vaccine Platform: Reaching Milestones of $6 Million NIH Grant
Vical Incorporated has successfully completed second-year milestones under a three-year, $6.0 million grant awarded in 2007, and is advancing with the development of a DNA vaccine manufacturing process with the potential to produce several million doses of vaccines in a matter of days.
The RapidResponse(tm) system is designed to allow extremely rapid and large-scale production of [...]
Antibody-Based HIV Vaccine: New Approaches
According to John R. Mascola, M.D., deputy director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, several recent studies suggest promising new research directions for the development of an antibody-based HIV vaccine. Attempts to create a vaccine that induces antibodies that prevent HIV [...]
DoD Explores New DNA Vaccine Delivery Method
Connie Schmaljohn, senior research scientist at the U.S. Army Medical Research Institute of Infectious Diseases, announced that DoD scientists are exploring a new DNA vaccine delivery method at the webcast “Armed with Science: Research and Applications for the Modern Military”.
“DNA offers a number of advantages over conventional vaccine approaches, especially with regard to biodefense vaccines. [...]
DNA Vaccines May Protect Against Pandemic Influenza
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine discovery, development and delivery, announced preclinical data from two studies of influenza DNA vaccines designed using its SynCon(TM) technology. The data indicated that the consensus H1N1 and H5N1 influenza vaccines achieved significant increases in immune response and provided protection against influenza virus strains not [...]
Pneumococcal Vaccine Program for Developing Countries
The current price of the pneumococcal vaccine is about $70 in US and European countries. The Advanced Market Commitment (AMC) program will provide incentive for pharmaceutical companies to develop vaccines against diseases raging in poor countries by guarantee of fixed price purchase. G8 countries - among them UK, Canada, Italy, Norway and Russia will invest [...]
